The drug Paxlovid has been shown to prevent severe Covid-19 in high-risk patients. But evidence on other outcomes such as illness duration, transmission risk, and long Covid is weak. One physician says companies must do new studies to fill this knowledge gap and maintain approval for these critical drugs.
↧